이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

다발성 골수종에 대한 Idecabtagene Vicleucel CAR-T 후 Iberdomide와 치료 중단 관찰 비교

2026년 10월 16일 업데이트: National Cancer Institute (NCI)

다발성 골수종 환자에서 Idecaptagene Vicleucel CAR-T에 따른 이베르도마이드 유지 요법에 대한 무작위 제2상 연구

This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell [CAR-T] therapy) for multiple myeloma. The usual approach after treatment with idecabtagene vicleucel is to monitor the multiple myeloma without giving myeloma medications. There is currently no medication approved specifically for use after idecabtagene vicleucel treatment. Upon administration, iberdomide modifies the immune system and activates immune cells called T-cells, which could enhance the effectiveness of idecabtagene vicleucel. Iberdomide may keep multiple myeloma under control for longer than the usual approach (disease monitoring) after idecabtagene vicleucel, and may help multiple myeloma patients live longer.

연구 개요

상세 설명

PRIMARY OBJECTIVES:

I. To establish and confirm the safety and dose of iberdomide as maintenance after idecabtagene vicleucel (ide-cel) CAR-T. (Safety run-in) II. To assess whether iberdomide maintenance therapy after idecabtagene vicleucel CAR-T cell therapy increases progression-free survival (PFS) relative to observation without additional therapy. (Randomized phase II)

SECONDARY OBJECTIVES:

I. To demonstrate anti-tumor activity, defined as conversion from non-minimal residual disease (MRD) complete response (CR)/stringent CR (sCR) status to MRD-negative CR/sCR, as well as improvement in PFS in the safety run-in cohort. (Safety run-in) II. To estimate the rate of conversion from MRD-positive at baseline to MRD-negative at any time point post-initiation of iberdomide maintenance or observation without additional therapy. (Key secondary objective; Randomized phase II) III. To estimate overall survival (OS) distribution post-initiation of iberdomide maintenance or observation without additional therapy. (Key secondary objective; Randomized phase II) IV. To estimate the minimal residual disease (MRD)-negativity rate at pre-registration and at one year post-initiation of iberdomide maintenance or observation without additional therapy. (Randomized phase II) V. To estimate rate of deepening hematological response among patients with measurable multiple myeloma (MM) post-initiation of iberdomide maintenance or observation without additional therapy. (Randomized phase II) VI. To evaluate the safety profile of iberdomide maintenance. (Randomized phase II) VII. To evaluate the peripheral blood immunophenotype before and during iberdomide maintenance or observation without additional therapy. (Randomized phase II) VIII. To evaluate persistence of CAR-T cells with iberdomide maintenance or observation without additional therapy. (Randomized phase II)

CORRELATIVE SCIENCE OBJECTIVES:

I. To estimate the minimal residual disease (MRD)-negativity rate at start of maintenance and at one year post-initiation of maintenance or observation.

II. To estimate the sustained MRD-negativity rate. III. To estimate the rate of conversion from MRD-positive to MRD-negative. (Key objective) IV. To evaluate the peripheral blood immunophenotype before and during maintenance therapy or observation.

V. To evaluate the persistence of CAR-T cells. VI. To evaluate B-cell maturation antigen (BCMA) protein expression by immunohistochemistry on myeloma cells from patients that have relapsed/recurrent disease.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP 1: Patients undergo disease monitoring at monthly clinic visits until disease progression. Patients also undergo bone marrow aspiration and biopsy throughout the trial, undergo collection of blood samples at screening and on study, and undergo positron emission tomography (PET)/computed tomography (CT) and/or skeletal survey x-ray, CT, or magnetic resonance imaging (MRI) at screening and then as clinically indicated.

GROUP 2: Patients receive iberdomide orally (PO) once daily (QD) on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy throughout the trial, undergo collection of blood samples at screening and on study, and undergo PET/CT and/or skeletal survey x-ray, CT, or MRI at screening and then as clinically indicated.

After completion of study treatment, patients are followed up within 30 days, then every 3-6 months until 4 years following registration.

연구 유형

중재적

등록 (추정된)

84

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • California
      • Irvine, California, 미국, 92612
        • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
      • Los Angeles, California, 미국, 90048
        • Cedars-Sinai Medical Center
      • Orange, California, 미국, 92868
        • UC Irvine Health/Chao Family Comprehensive Cancer Center
      • Sacramento, California, 미국, 95817
        • University of California Davis Comprehensive Cancer Center
    • Georgia
      • Augusta, Georgia, 미국, 30912
        • Augusta University Medical Center
    • Illinois
      • Chicago, Illinois, 미국, 60612
        • University of Illinois
    • Iowa
      • Ankeny, Iowa, 미국, 50023
        • UI Health Care Mission Cancer and Blood - Ankeny Clinic
      • Clive, Iowa, 미국, 50325
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
      • Des Moines, Iowa, 미국, 50309
        • Iowa Methodist Medical Center
      • Des Moines, Iowa, 미국, 50314
        • Mercy Medical Center - Des Moines
      • Des Moines, Iowa, 미국, 50309
        • UI Health Care Mission Cancer and Blood - Des Moines Clinic
      • Des Moines, Iowa, 미국, 50314
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
      • Waukee, Iowa, 미국, 50263
        • UI Health Care Mission Cancer and Blood - Waukee Clinic
    • Mississippi
      • Southhaven, Mississippi, 미국, 38671
        • Baptist Memorial Hospital and Cancer Center-Desoto
    • Missouri
      • City of Saint Peters, Missouri, 미국, 63376
        • Siteman Cancer Center at Saint Peters Hospital
      • Creve Coeur, Missouri, 미국, 63141
        • Siteman Cancer Center at West County Hospital
      • St Louis, Missouri, 미국, 63110
        • Washington University School of Medicine
      • St Louis, Missouri, 미국, 63129
        • Siteman Cancer Center-South County
      • St Louis, Missouri, 미국, 63136
        • Siteman Cancer Center at Christian Hospital
    • Nebraska
      • Bellevue, Nebraska, 미국, 68123
        • Nebraska Medicine-Bellevue
      • Omaha, Nebraska, 미국, 68198
        • University of Nebraska Medical Center
      • Omaha, Nebraska, 미국, 68118
        • Nebraska Medicine-Village Pointe
    • New Jersey
      • Middletown, New Jersey, 미국, 07748
        • Memorial Sloan Kettering Monmouth
      • Montvale, New Jersey, 미국, 07645
        • Memorial Sloan Kettering Bergen
    • New York
      • Commack, New York, 미국, 11725
        • Memorial Sloan Kettering Commack
      • Harrison, New York, 미국, 10604
        • Memorial Sloan Kettering Westchester
      • New York, New York, 미국, 10065
        • Memorial Sloan Kettering Cancer Center
    • North Carolina
      • Chapel Hill, North Carolina, 미국, 27599
        • UNC Lineberger Comprehensive Cancer Center
      • Charlotte, North Carolina, 미국, 28203
        • Carolinas Medical Center/Levine Cancer Institute
      • Charlotte, North Carolina, 미국, 28210
        • Atrium Health Pineville/LCI-Pineville
      • Charlotte, North Carolina, 미국, 28262
        • Atrium Health University City/LCI-University
      • Concord, North Carolina, 미국, 28025
        • Atrium Health Cabarrus/LCI-Concord
      • Huntersville, North Carolina, 미국, 28078
        • Levine Cancer Institute - Huntersville
      • Monroe, North Carolina, 미국, 28112
        • Atrium Health Union/LCI-Union
      • Winston-Salem, North Carolina, 미국, 27157
        • Wake Forest University Health Sciences
    • North Dakota
      • Fargo, North Dakota, 미국, 58122
        • Sanford Roger Maris Cancer Center
      • Fargo, North Dakota, 미국, 58122
        • Sanford Broadway Medical Center
    • Oklahoma
      • Oklahoma City, Oklahoma, 미국, 73104
        • University of Oklahoma Health Sciences Center
    • Oregon
      • Portland, Oregon, 미국, 97213
        • Providence Portland Medical Center
      • Portland, Oregon, 미국, 97225
        • Providence Saint Vincent Medical Center
    • Pennsylvania
      • Danville, Pennsylvania, 미국, 17822
        • Geisinger Medical Center
    • South Carolina
      • Greenville, South Carolina, 미국, 29615
        • Prisma Health Cancer Institute - Eastside
    • Tennessee
      • Memphis, Tennessee, 미국, 38120
        • Baptist Memorial Hospital and Cancer Center-Memphis
    • Texas
      • Baytown, Texas, 미국, 77521
        • Houston Methodist San Jacinto Hospital
      • Cypress, Texas, 미국, 77429
        • Houston Methodist Cypress Hospital
      • Houston, Texas, 미국, 77030
        • Houston Methodist Hospital
      • Houston, Texas, 미국, 77070
        • Methodist Willowbrook Hospital
      • Houston, Texas, 미국, 77094
        • Houston Methodist West Hospital
      • Nassau Bay, Texas, 미국, 77058
        • Houston Methodist Saint John Hospital
      • Sugar Land, Texas, 미국, 77479
        • Houston Methodist Sugar Land Hospital
      • The Woodlands, Texas, 미국, 77385
        • Houston Methodist The Woodlands Hospital
    • Vermont
      • Burlington, Vermont, 미국, 05401
        • University of Vermont Medical Center
      • Burlington, Vermont, 미국, 05405
        • University of Vermont and State Agricultural College
    • Washington
      • Edmonds, Washington, 미국, 98026
        • Swedish Cancer Institute-Edmonds
      • Issaquah, Washington, 미국, 98029
        • Swedish Cancer Institute-Issaquah
      • Seattle, Washington, 미국, 98122
        • Swedish Medical Center-First Hill
      • Seattle, Washington, 미국, 98109
        • Fred Hutchinson Cancer Center
    • Wisconsin
      • Burlington, Wisconsin, 미국, 53105
        • Aurora Cancer Care-Southern Lakes VLCC
      • Cudahy, Wisconsin, 미국, 53110
        • Aurora Saint Luke's South Shore
      • Germantown, Wisconsin, 미국, 53022
        • Aurora Health Care Germantown Health Center
      • Grafton, Wisconsin, 미국, 53024
        • Aurora Cancer Care-Grafton
      • Green Bay, Wisconsin, 미국, 54311
        • Aurora BayCare Medical Center
      • Kenosha, Wisconsin, 미국, 53142
        • Aurora Cancer Care-Kenosha South
      • Marinette, Wisconsin, 미국, 54143
        • Aurora Bay Area Medical Group-Marinette
      • Milwaukee, Wisconsin, 미국, 53209
        • Aurora Cancer Care-Milwaukee
      • Milwaukee, Wisconsin, 미국, 53215
        • Aurora Saint Luke's Medical Center
      • Milwaukee, Wisconsin, 미국, 53233
        • Aurora Sinai Medical Center
      • Oshkosh, Wisconsin, 미국, 54904
        • Vince Lombardi Cancer Clinic - Oshkosh
      • Racine, Wisconsin, 미국, 53406
        • Aurora Cancer Care-Racine
      • Sheboygan, Wisconsin, 미국, 53081
        • Vince Lombardi Cancer Clinic-Sheboygan
      • Summit, Wisconsin, 미국, 53066
        • Aurora Medical Center in Summit
      • Two Rivers, Wisconsin, 미국, 54241
        • Vince Lombardi Cancer Clinic-Two Rivers
      • Wauwatosa, Wisconsin, 미국, 53226
        • Aurora Cancer Care-Milwaukee West
      • West Allis, Wisconsin, 미국, 53227
        • Aurora West Allis Medical Center

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • PRE-REGISTRATION ELIGIBILITY CRITERIA (STEP 0):

  • All patients must be pre-registered. For patients who consent to biobanking, submit the bone marrow and blood specimens

    • Note: Patients who do not consent to the optional biobanking must be pre-registered, but specimens should not be submitted for these patients
    • Please ensure patient has suspected diagnosis of multiple myeloma and meets on study guidelines prior to informed consent and biospecimen collection
    • In cases where the bone marrow aspiration may be inadequate at Step 0 registration, the patient may still register on study
  • ELIGIBILITY CRITERIA (STEP 1):

  • Patients must have diagnostically confirmed MM in response status of stable disease or better by International Myeloma Working Group (IMWG) criteria at day 80-110 post-infusion of ide-cel. Patients in deep remission (e.g., CR, MRD-negative, etc.), are eligible

  • All patients are required to have received ide-cel CAR-T within 80-110 days of registration

  • Adverse events related to ide-cel are required to have resolved to grade =< 1 except fatigue, alopecia, and other events that are unlikely to interfere with study assessments or pose a safety risk to participants

  • Patients must have had ≥ 2 lines of therapy for MM (this includes proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody)

  • Prior therapy with iberdomide is permitted but prior iberdomide refractoriness is prohibited. Refractoriness is defined as per published IMWG criteria; progression while on iberdomide or within 60 days of stopping iberdomide

  • Patients who have received MM-directed therapy since ide-cel infusion are not eligible, with the exception of short-course steroids for managing ide-cel toxicity as described below

  • Age ≥ 18 years

  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

  • Absolute neutrophil count (ANC) ≥ 1,500/mm^3

    • Platelet transfusions or use of growth factors for neutropenia (e.g., filgrastim, tbo-filgrastim, sagramostim) or thrombocytopenia (romiplostim or eltrombopag) are not permitted to meet enrollment criteria. Specific cutoffs are one week for short-acting myeloid growth factors for neutropenia, and two weeks for all platelet growth factors or long-acting (usually pegylated) myeloid growth factors
  • Platelet count ≥ 75,000/mm^3

    • Platelet transfusions or use of growth factors for neutropenia (e.g., filgrastim, tbo-filgrastim, sagramostim) or thrombocytopenia (romiplostim or eltrombopag) are not permitted to meet enrollment criteria. Specific cutoffs are one week for short-acting myeloid growth factors for neutropenia, and two weeks for all platelet growth factors or long-acting (usually pegylated) myeloid growth factors
  • Calculated (calc.) creatinine clearance >= 30 mL/min by Modification of Diet in Renal Disease (MDRD)

    • Platelet transfusions or use of growth factors for neutropenia (e.g., filgrastim, tbo-filgrastim, sagramostim) or thrombocytopenia (romiplostim or eltrombopag) are not permitted to meet enrollment criteria. Specific cutoffs are one week for short-acting myeloid growth factors for neutropenia, and two weeks for all platelet growth factors or long-acting (usually pegylated) myeloid growth factors
  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN)

    • Platelet transfusions or use of growth factors for neutropenia (e.g., filgrastim, tbo-filgrastim, sagramostim) or thrombocytopenia (romiplostim or eltrombopag) are not permitted to meet enrollment criteria. Specific cutoffs are one week for short-acting myeloid growth factors for neutropenia, and two weeks for all platelet growth factors or long-acting (usually pegylated) myeloid growth factors
  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) ≤ 3 x upper limit of normal (ULN)

    • Platelet transfusions or use of growth factors for neutropenia (e.g., filgrastim, tbo-filgrastim, sagramostim) or thrombocytopenia (romiplostim or eltrombopag) are not permitted to meet enrollment criteria. Specific cutoffs are one week for short-acting myeloid growth factors for neutropenia, and two weeks for all platelet growth factors or long-acting (usually pegylated) myeloid growth factors
  • Not pregnant and not nursing, because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effect on the developing fetus and newborn are unknown.

    • FCBP (female of childbearing potential) is a female who: 1) has achieved menarche (first menstrual cycle) at some point, 2) has not undergone a hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time during the preceding 24 consecutive months).

    • Females of childbearing potential (FCBP):

      • Must use a contraceptive method that is highly effective (with a failure rate of < 1% per year), preferably with low user dependency during the intervention period and for at least 28 days after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.
      • The effects of iberdomide on the developing human fetus are unknown. Immunodulatory derivative (IMiD) agents as well as other therapeutic agents used in this trial are known to be teratogenic. Females of child-bearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10-14 days prior to, and again within 24 hours of starting iberdomide, and must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control, one highly effective method and one additional effective method at the same time, at least 28 days before she starts taking iberdomide. Examples of highly effective methods are intrauterine device, hormonal contraceptives, tubal ligation, or partner's vasectomy. Examples of barrier method are male condom, diaphragm, or cervical cap. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risk of fetal exposure.
      • Should a woman become pregnant or suspect she is pregnant while she or her partner are participating in this study, she should inform her treating physician immediately. FCBP must use adequate contraception for at least 28 days after discontinuation from study. Because of the potential for serious adverse reactions in a breastfed child, women are advised not to breastfeed during treatment and for at least 28 days after the last dose.
      • The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with a nearly undetected pregnancy.
    • Non-childbearing potential is defined as follows (by other than medical reasons):

      • ≥ 45 years of age and has not had menses for > 1 year
      • Patients who have been amenorrhoeic for < 2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation
      • Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure
  • Male patients must agree to use an adequate method of contraception for the duration of the study and for 28 days afterwards.

    • Male participants: contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies:

      • Male participants are eligible to participate if they agree to the following during the intervention period and for 28 days after the last dose of study treatment to allow for clearance of any altered sperm:

        • Refrain from donating sperm

PLUS, either:

  • Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR

  • Must agree to use contraception/barrier as detailed below:

    • Agree to use a male condom, even if they have undergone a successful vasectomy, and female partner to use an additional highly effective contraceptive method with a failure rate of < 1% per year as when having sexual intercourse with a woman of childbearing potential (including pregnant females)

      • Patients may not have polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome or amyloidosis involving any vital organ; amyloidosis found in skin or lymph nodes ("non-vital organs"), or incidental observation of amyloidosis on bone marrow biopsy, are both permissible. Plasma cell leukemia is permissible for study enrollment
      • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
      • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible for this trial
      • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
      • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. Patients with HCV infection who are currently on treatment are eligible if they have an undetectable HCV viral load
      • Patients may not have other, active infections at time of study registration. Recent infections are not exclusionary if antibiotics have been completed and infection is considered to be resolved / controlled. (Chronic maintenance antibiotics for prior infections, such as fungal, are permissible.)
      • No known allergy to iberdomide
      • No known medical condition causing an inability to swallow oral formulations of agents
      • Patients receiving other active therapies for MM since ide-cel infusion are prohibited from participating in the study
      • Corticosteroids used for the purpose of managing ide-cel toxicity (often neurotoxicity) soon after ide-cel administration are acceptable, provided that the participant will have been off corticosteroids for > 30 days by cycle 1 day 1. Physiologically dosed chronic steroids are permitted
      • Given the potential for interaction with iberdomide, patients who take strong CYP3A4 inducers or inhibitors may enroll after switching to a different agent and after an appropriate washout period for that particular medication, ideally three half-lives, prior to cycle 1 day 1

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: Group 1 (monitoring)

Patients undergo disease monitoring at monthly clinic visits until disease progression. Patients also undergo bone marrow aspiration and biopsy throughout the trial, undergo collection of blood samples at screening and on study, and undergo PET/CT and/or skeletal survey x-ray, CT, or MRI at screening and then as clinically indicated.

Undergo bone marrow biopsy

다른 이름들:
  • 골수 생검
  • 생검, 골수

Undergo MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 의료영상, 자기공명 / 핵자기공명
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 핵자기공명영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI

Undergo bone marrow aspiration

Undergo collection of blood samples

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집
  • 샘플 수집

Undergo PET/CT

다른 이름들:
  • 의료 영상, 양전자 방출 단층 촬영
  • 애완 동물
  • PET 스캔
  • 양전자 방출 단층 촬영 스캔
  • 양전자 방출 단층 촬영
  • PT
  • 양전자방출단층촬영(시술)

Undergo PET/CT and/or CT

다른 이름들:
  • CT
  • 고양이
  • 고양이 스캔
  • 컴퓨터 축 단층 촬영
  • 전산화 단층 촬영
  • CT 스캔
  • 단층 촬영
  • 컴퓨터 축 단층 촬영(시술)
  • 컴퓨터 단층촬영(CT) 스캔
  • 진단 CAT 스캔
  • 진단 CAT 스캔 서비스 유형

Undergo disease monitoring

다른 이름들:
  • 감시 장치
  • 의료 모니터링

Undergo skeletal survey x-ray

다른 이름들:
  • 골격 조사
실험적: Group II (iberdomide)

Patients receive iberdomide PO QD on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy throughout the trial, undergo collection of blood samples at screening and on study, and undergo PET/CT and/or skeletal survey x-ray, CT, or MRI at screening and then as clinically indicated.

Undergo bone marrow biopsy

다른 이름들:
  • 골수 생검
  • 생검, 골수

Undergo MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 의료영상, 자기공명 / 핵자기공명
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 핵자기공명영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI

Undergo bone marrow aspiration

Undergo collection of blood samples

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집
  • 샘플 수집

Undergo PET/CT

다른 이름들:
  • 의료 영상, 양전자 방출 단층 촬영
  • 애완 동물
  • PET 스캔
  • 양전자 방출 단층 촬영 스캔
  • 양전자 방출 단층 촬영
  • PT
  • 양전자방출단층촬영(시술)

Given PO

다른 이름들:
  • CC-220
  • CC 220
  • Zenbexus

Undergo PET/CT and/or CT

다른 이름들:
  • CT
  • 고양이
  • 고양이 스캔
  • 컴퓨터 축 단층 촬영
  • 전산화 단층 촬영
  • CT 스캔
  • 단층 촬영
  • 컴퓨터 축 단층 촬영(시술)
  • 컴퓨터 단층촬영(CT) 스캔
  • 진단 CAT 스캔
  • 진단 CAT 스캔 서비스 유형

Undergo skeletal survey x-ray

다른 이름들:
  • 골격 조사

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
용량 제한 독성 발생률(안전성 침해)
기간: 치료 첫 3개월
치료 첫 3개월
Progression-free survival (PFS) (randomized phase II)
기간: From randomization to the time of progression and/or death, assessed up to 4 years

Final analyses will use log-rank test statistics to compare the PFS distributions between the treatment arms. Will also evaluate differences in PFS between the treatment arms using a stratified log-rank test. In addition, the methods of Kaplan and Meier will be used to graphically evaluate these distributions as well as to estimate the median PFS and corresponding 95% confidence intervals. Further, will also estimate the 1- and 2-year PFS rates for each treatment arm along with corresponding 95% confidence intervals. Finally, Cox proportional hazards models will be used to evaluate the impact of treatment arm on PFS.

From randomization to the time of progression and/or death, assessed up to 4 years

2차 결과 측정

결과 측정
측정값 설명
기간
Incidence of adverse events
기간: Up to 4 years

Adverse events will be collected and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 criteria. For CTCAE data, the maximum grade for each type of adverse will be recorded for each patient, and described using frequency tables. All-cause adverse events will be summarized as well as treatment-related adverse events, with particular focus on grade 3+ non-hematologic adverse events and grade 4+ hematologic events. Frequency tables will be reviewed to identify patterns. The overall adverse event severity will be compared between treatment arms using a chi-square test (or Fisher's exact test if the data in contingency table is sparse).

Up to 4 years
Number of treatment cycles received (tolerability)
기간: Up to 4 years

Will be summarized.

Up to 4 years
Proportion of patients with dose modifications, omissions, and/or delays (tolerability)
기간: Up to 4 years

Will be summarized.

Up to 4 years
Proportion of patients who go off treatment due to adverse events
기간: Up to 4 years

Will be summarized.

Up to 4 years
Overall survival (OS)
기간: From randomization until death from any cause, assessed up to 4 years

The Kaplan-Meier method will be used to estimate OS for each treatment arm, with 1- and 2-year OS estimates and OS medians along with their 95% confidence intervals. For the comparison of the treatment arms, will use a one-sided log-rank test to compare the OS distributions between treatment arms. Will also evaluate the influence of arm on OS using stratified and unstratified multivariable Cox proportional hazards models.

From randomization until death from any cause, assessed up to 4 years
Best response achieved while on study
기간: Up to 4 years

Will calculate these rates by treatment arm along with corresponding 95% binomial confidence intervals. Logistic regression models may also be used to assess differences in the ability to deepen or convert to a response between treatment arms. Minimal residual disease (MRD) will be assessed as an aspect of response assessment.

Up to 4 years
Proportion of patients who improve their status
기간: After randomization, up to 4 years

Will calculate these rates by treatment arm along with corresponding 95% binomial confidence intervals. Logistic regression models may also be used to assess differences in the ability to deepen or convert to a response between treatment arms. MRD will be assessed as an aspect of response assessment.

After randomization, up to 4 years

기타 결과 측정

결과 측정
측정값 설명
기간
키메라 항원 수용체 T세포의 지속성
기간: 12주기에서
12주기에서
MRD-negativity rate
기간: At start of maintenance and at one year post-initiation of maintenance or observation

Will evaluate and identify patients in MRD-negative complete response (CR)/stringent CR (sCR) versus patients who are not in MRD-negative CR/sCR, both from pre-registration (before start of maintenance iberdomide vs. active monitoring) and at the follow-up time points. These will be summarized as proportions within each of the randomization arms at each time point. Assuming that the number of MRD-negative CR/sCR patients is binomially distributed, will calculate corresponding 95% binomial confidence intervals for these rates as well.

At start of maintenance and at one year post-initiation of maintenance or observation
Sustained MRD-negativity rate
기간: Up to 4 years

Will evaluate and identify patients in MRD-negative CR/sCR versus patients who are not in MRD-negative CR/sCR, both from pre-registration (before start of maintenance iberdomide vs. active monitoring) and at the follow-up time points. These will be summarized as proportions within each of the randomization arms at each time point. Assuming that the number of MRD-negative CR/sCR patients is binomially distributed, will calculate corresponding 95% binomial confidence intervals for these rates as well.

Up to 4 years
Rate of conversion from MRD-positive to MRD-negative
기간: Up to 4 years

Will assess the proportion of patients who had detectable disease at randomization who were able to achieve MRD-negative CR/sCR status after treatment with iberdomide.

Up to 4 years
Peripheral blood immunophenotype
기간: Before and during maintenance therapy or observation

Continuous measures of immune cell subsets will be evaluated using side-by-side boxplots to show differences between treatment arms, and two-sample t-tests will be used to assess quantitative differences in the mean levels of these measures between arms.

Before and during maintenance therapy or observation
B-cell maturation antigen (BCMA) protein expression
기간: Up to 4 years

Will evaluate protein expression by immunohistochemistry on myeloma cells from patients that have relapsed/recurrent disease. Will summarize the BCMA expression status at baseline and evaluate how these associate with PFS using Cox regression models, to evaluate how treatment arm may modify this influence. Changes in this status can be captured both graphically as well as a time-dependent covariate in the model for PFS. In a similar manner, will also evaluate expression intensity. This will be done in those with BCMA expression present, but also across all patients. Differences in changes in these expression intensity levels before versus after study registration monitoring will be compared between treatment arms. Changes in this status will also be evaluated and how these may differ between patients treated with maintenance iberdomide vs. active monitoring using logistic generalized estimating equation models.

Up to 4 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Sascha A Tuchman, Alliance for Clinical Trials in Oncology

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 8월 27일

기본 완료 (추정된)

2030년 3월 1일

연구 완료 (추정된)

2030년 3월 1일

연구 등록 날짜

최초 제출

2023년 12월 21일

QC 기준을 충족하는 최초 제출

2023년 12월 21일

처음 게시됨 (실제)

2023년 12월 22일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 19일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 16일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

"NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page."

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다